MA33913B1 - Utilisation thérapeutique de conjugues proteines-polymeres - Google Patents

Utilisation thérapeutique de conjugues proteines-polymeres

Info

Publication number
MA33913B1
MA33913B1 MA35051A MA35051A MA33913B1 MA 33913 B1 MA33913 B1 MA 33913B1 MA 35051 A MA35051 A MA 35051A MA 35051 A MA35051 A MA 35051A MA 33913 B1 MA33913 B1 MA 33913B1
Authority
MA
Morocco
Prior art keywords
protein
polymer
facilities
therapeutic use
essential
Prior art date
Application number
MA35051A
Other languages
Arabic (ar)
English (en)
Inventor
Ko-Chung Lin
Rudolf Dr Widmann
Original Assignee
Pharmaessentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaessentia Corp filed Critical Pharmaessentia Corp
Publication of MA33913B1 publication Critical patent/MA33913B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation des conjugués protéines-polymères décrits dans le mémoire descriptif, à des fins de traitement de diverses maladies, dont la myélofibrose idiopathique, la polyglobulie essentielle et la thrombocytémie essentielle.
MA35051A 2009-12-10 2010-12-09 Utilisation thérapeutique de conjugues proteines-polymeres MA33913B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28541109P 2009-12-10 2009-12-10
PCT/US2010/059714 WO2011072138A2 (fr) 2009-12-10 2010-12-09 Utilisation thérapeutique de conjugués protéines-polymères

Publications (1)

Publication Number Publication Date
MA33913B1 true MA33913B1 (fr) 2013-01-02

Family

ID=44146181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35051A MA33913B1 (fr) 2009-12-10 2010-12-09 Utilisation thérapeutique de conjugues proteines-polymeres

Country Status (32)

Country Link
US (1) US8617532B2 (fr)
EP (1) EP2509593B1 (fr)
JP (1) JP5547816B2 (fr)
KR (1) KR101782084B1 (fr)
CN (1) CN102724980B (fr)
AR (1) AR079369A1 (fr)
AU (1) AU2010328067B2 (fr)
BR (1) BR112012014017B1 (fr)
CA (1) CA2782624C (fr)
CL (1) CL2012001503A1 (fr)
CY (1) CY1122901T1 (fr)
DK (1) DK2509593T3 (fr)
EA (1) EA022354B9 (fr)
ES (1) ES2786025T3 (fr)
HR (1) HRP20200678T1 (fr)
HU (1) HUE049051T2 (fr)
IL (1) IL220249A0 (fr)
LT (1) LT2509593T (fr)
MA (1) MA33913B1 (fr)
MX (1) MX337705B (fr)
MY (1) MY169961A (fr)
NZ (1) NZ600528A (fr)
PL (1) PL2509593T3 (fr)
PT (1) PT2509593T (fr)
RS (1) RS60336B1 (fr)
SG (1) SG181084A1 (fr)
SI (1) SI2509593T1 (fr)
SM (1) SMT202000239T1 (fr)
TN (1) TN2012000256A1 (fr)
UA (1) UA109646C2 (fr)
WO (1) WO2011072138A2 (fr)
ZA (1) ZA201205056B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6820841B2 (ja) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション ペグ化インターフェロンのための投薬計画

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
AU2007358605B8 (en) * 2007-09-04 2012-02-02 Biosteed Gene Expression Tech. Co., Ltd. Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method

Also Published As

Publication number Publication date
BR112012014017A2 (pt) 2016-04-12
KR20120110105A (ko) 2012-10-09
MX2012006132A (es) 2012-06-19
JP5547816B2 (ja) 2014-07-16
CN102724980A (zh) 2012-10-10
AR079369A1 (es) 2012-01-18
EP2509593A4 (fr) 2016-01-13
WO2011072138A2 (fr) 2011-06-16
MY169961A (en) 2019-06-19
US8617532B2 (en) 2013-12-31
CY1122901T1 (el) 2021-05-05
KR101782084B1 (ko) 2017-09-26
AU2010328067B2 (en) 2014-10-02
CN102724980B (zh) 2014-10-15
BR112012014017B1 (pt) 2021-10-26
SI2509593T1 (sl) 2020-07-31
CA2782624C (fr) 2016-11-01
LT2509593T (lt) 2020-05-25
CL2012001503A1 (es) 2012-11-09
TN2012000256A1 (en) 2013-12-12
UA109646C2 (uk) 2015-09-25
RS60336B1 (sr) 2020-07-31
ZA201205056B (en) 2013-03-27
MX337705B (es) 2016-03-15
EP2509593A2 (fr) 2012-10-17
IL220249A0 (en) 2012-07-31
EP2509593B1 (fr) 2020-02-12
HRP20200678T1 (hr) 2020-10-02
EA022354B1 (ru) 2015-12-30
CA2782624A1 (fr) 2011-06-16
US20110262380A1 (en) 2011-10-27
SG181084A1 (en) 2012-07-30
PL2509593T3 (pl) 2020-08-24
EA022354B9 (ru) 2016-02-29
HUE049051T2 (hu) 2020-09-28
DK2509593T3 (da) 2020-05-11
JP2013513611A (ja) 2013-04-22
ES2786025T3 (es) 2020-10-08
NZ600528A (en) 2014-01-31
SMT202000239T1 (it) 2020-07-08
PT2509593T (pt) 2020-04-21
AU2010328067A1 (en) 2012-07-05
EA201200865A1 (ru) 2012-11-30
WO2011072138A9 (fr) 2011-10-06
HK1176015A1 (en) 2013-07-19

Similar Documents

Publication Publication Date Title
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
MA34277B1 (fr) Pyrrolobenzodiazépines et conjugués de celles-ci
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
IL227990A0 (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2'6-dione in treatment of immune-related and inflammatory diseases
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
EP2486060A4 (fr) Anticorps anti-siglec 15 dans le traitement de maladies liées à une perte osseuse
TW200732347A (en) VEGF analogs and methods of use
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
ECSP099514A (es) Antagonistas de activina-actrii y usos para aumentar los niveles de glóbulos rojos
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EP1951319A4 (fr) Immunorecepteur chimerique utile dans le traitement de cancers humains
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CR20160355A (es) Anticuerpos neutralizantes de atomegalovirus humanos y uso de los mismos
EA201691399A1 (ru) Способы и готовые лекарственные формы для лечения болезни альцгеймера
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
EA200701511A1 (ru) Фармацевтические композиции бендамустина, предназначенные для лиофилизации
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201270480A1 (ru) Новые соединения
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.